Reducing the Risk of Hepatitis B-Associated Chronic Liver Disease and Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 1063
Special Issue Editor
Special Issue Information
Dear Colleagues,
Chronic hepatitis B therapeutics have focused upon the development of direct acting anti-viral compounds that have reduced virus load as well as the intensity and duration of chronic liver disease (CLD). However, sterilizing cures have not been achieved, and hepatitis B virus (HBV) carriers are still at elevated risk for the reappearance of CLD and progression to hepatocellular carcinoma (HCC) associated with the emergence of drug resistance, with drug-induced immunosuppression, altered host–virus relationship associated with gut dysbiosis, and with the persistence/reactivation of occult infections. The pathogenesis of CLD is immune-mediated, although relatively little attention has been made to developing drugs that directly target CLD alone or in combination with direct acting antiviral compounds. These represent challenges at the forefront of next-generation therapeutic development to achieve a functional cure that is characterized by sustained virus suppression, amelioration of CLD, and reduced risk for CLD progression to HCC.
Prof. Dr. Mark A. Feitelson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HBsAg loss
- prolonged nucleoside therapy
- autoimmune diseases
- gut dysbiosis
- hepatitis delta coinfection
- HIV coinfection
- functional cure
- immunomodulation
- HBV integration
- immune-mediated CLD
- combination therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
